Data as of Jan 23
| +0.18 / +0.15%|
The 24 analysts offering 12-month price forecasts for Celgene have a median target of 128.50, with a high estimate of 150.00 and a low estimate of 71.00. The median estimate represents a +3.72% increase from the last price of 123.89.
The current consensus among 28 polled investment analysts is to Buy stock in Celgene. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.